cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Bayu Brahma
Contact Email
journal.cancer@gmail.com
Phone
+628176389956
Journal Mail Official
admin@indonesianjournalofcancer.or.id
Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta
Location
Kota adm. jakarta barat,
Dki jakarta
INDONESIA
Indonesian Journal of Cancer
Published by National Cancer Center-Dharmais Cancer Hospital
ISSN : 19783744     EISSN : 23556811     DOI : https://www.doi.org/ 10.33371
Core Subject : Health, Science,
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Public Health
Indonesian Journal of Cancer is a peer-reviewed and open-access journal. This journal is published quarterly (in March, June, September, and December) by Dharmais Cancer Hospital - National Cancer Center. Submissions are reviewed under a broad scope of topics relevant to experimental and clinical cancer research. Articles are original research that needs to be disseminated and written in English. All submitted manuscripts will go through the double-blind peer review and editorial review before being granted acceptance for publication. The journal publishes original research articles, case reports, and review articles under the following categories: cancer management, cancer prevention, cancer etiology, epidemiology, molecular oncology, cancer diagnosis and therapy, tumor pathology, surgical oncology, medical oncology, radiation oncology, interventional radiology, as well as early detection.
Arjuna Subject : Kedokteran - Onkologi
Articles 562 Documents
 27   28   29   30   31 
Cancer Stem Cell: Target Baru Obat Antikanker DANNY HALIM; TONO DJUWANTONO; TRI HANGGONO AHMAD
Indonesian Journal of Cancer Vol 4, No 3 (2010): Jul - Sep 2010
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v4i3.108

Abstract

Relaps, resistance and metastasis has become prominent problems that oncologists and cancer patients have to dealt with. Various studies have been done previously concluded that there are a subpopulation of cancer cells, identified as cancer stem cell, most likely to be the cause of relaps, resistance and metastasis of cancer. Cancer stem cell is a subpopulation of cancer cells that possess tumorigenicity, hence it can initiate the growth of tumor. Cancer stem cell has been suspected to be originated from normal stem cells reside in mature tissues, or from progenitor cells that gone through some series of alterations on its characteristics, including mutagenic and non-mutagenic changes. As seen in normal stem cells, cancer stem cell is also oftenly found in its inactive state. Therefore, cancer stem cell is not affected when it treated with many chemotherapeutic agents that are targeting cancer cells that proliferate extensively. Eventually, this event leads to the incidence of cancer relaps on cancer patients who already had series of cancer therapy. Based on this knowledge, it can be concluded that the only absolute way to overcome the incidence of metastasis, resistance and relaps on cancer patients, is to targeting cancer stem cell. Therefore, optimization on protocols of cancer stem cell identification and isolation strived continously. Some molecular markers that are oftenly used as a standard on cancer stem cell isolation are CD34, CD44 and CD133. In line with that, isolation methods that are based on sphere formation and the absorption of coloring dye could also be done to obtain cancer stem cell population. This review article would like to explain the nature of cancer stem cell existence, the pathology underlies its formation, characteristics and identification techniques that are commonly used, and challenges that have to be faced by scientists and physicians in order to optimize the application of cancer stem cell theory for the progress of science and patients sake.
Gizi dan Kanker Evy Damayanthi
Indonesian Journal of Cancer Vol 2, No 3 (2008): Jul - Sep 2008
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v2i3.52

Abstract

Kanker merupakan suatu penyakit tidak menular yang prevalensinya semakin meningkat. Kanker adalah suatu pertumbunan maligna yang selnya memiliki sifat-sifat : replikasi terus menerus, hilangnya kontak penghambatan, invasif and kemampuannya untuk menyebar, jika tidak ditangani maka akan menjadi fatal. Faktor lingkungan merupakan penyebab kejadian kanker sebesar 80 - 85 %, sedangkan sekitar 10 -15 % disebabkan oleh kesalahan replikasi dan genetika. Diyakini pula sepertiga dari semua kanker berhubungan dengan diet. World Cancer Research Fund dan American Institute for Cancer Research pada tahun 2007 menerbitkan "Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective". Di sana terdapat 8 rekomendasi dan 2 rekomendasi khusus guna mencegah dan mengendalikan penyakit kanker di dunia. Aktivitas antitumor yang dimiliki berbagai bahan pangan sangat berguna dalam upaya menurunkan kesempatan pengembangan kanker. Nutraceutical tersebut dapat efektif mencegah penyakit kanker jika dikonsumsi sebagai makanan bukan suplemen.Kata Kunci: kanker, nutrisi, aktivitas fisik, makanan, dan nutraceutikal
Pemeriksaan Rapid Urinary Bladder Cancer Antigen untuk Deteksi Karsinoma Sel Transisional Buli pada Populasi Indonesia (Penelitian Awal) Hery Tiera; Rainy Umbas
Indonesian Journal of Cancer Vol 7, No 2 (2013): Apr - Jun 2013
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (332.785 KB) | DOI: 10.33371/ijoc.v7i2.279

Abstract

PemeriksaanUrinary Bladder Cancer Antigen(UBC) merupakan salah satu pemeriksaan non-invasif terbaru dalam mendeteksi karsinoma buli dengan mengidentifikasi ekspresi sitokeratin 8 dan 18 di dalam urin. Tujuan penelitian ini adalah uji diagnostik dari pemeriksaanRapid UBCpada populasi Indonesia dengan kecurigaan klinis tumor buli.Penelitian ini mengevaluasi 21 pasien secara prospektif di rumah sakit pusat rujukan nasional Indonesia pada 2011- 2012. Sebagai kriteria inklusi adalah pasien usia di atas 18 tahun dengangross hematuriadan hasil pemeriksaan imajing menunjukkan adanya tumor buli, atau pasien Karsinoma Sel Transisional (KST) buli dengan riwayat reseksi tumor buli habis yang menjalanifollow upsistoskopi rutin. Kriteria eksklusi meliputi pasien dengan infeksi saluran kemih atau dengan hasil pemeriksaan bakteri tahan asam di urin positif. PemeriksaanRapid UBCdilakukan sebelum sistoskopi dilakukan. Hasil pemeriksaan selanjutnya dibandingkan dengan hasil sistoskopi dan histopatologi. Analisis statistik dilakukan dengan perbandingan bivariat menggunakan SPSS v.17.0.Mayoritas subjek penelitian adalah laki-laki (71,4%). Nilai rerata usia adalah 56,1 15,4 tahun. Lima belas pasien (71,4%) memiliki hasil UBC positif, dan 6 pasien (28,6%) memiliki hasil UBC negatif. Di antara pasien dengan hasil positif tersebut, 93,3% memiliki penemuan sistoskopi positif tumor buli dengan hasil histopatologi menunjukkan positif kasinoma sel transisional buli, dan 1 pasien memiliki hasil sistoskopi dan histopatologi negatif. Di antara pasien dengan hasil UBC negatif, 83,3% memiliki hasil sistoskopi positif menunjukkan adanya tumor buli dan hasil histopatologi karsinoma sel transisional buli. Satu pasien memiliki hasil sistoskopi dan histopatologi negatif. Nilaipositif predictive valuepemeriksaan rapid UBC dalam mendeteksi KST buli adalah 93,3% dan nilainegative predictive valueadalah 16,7%. Sensitivitas rapid UBC dalam penelitian ini sebesar 73,7% dan spesifisitas 50%, p=0,5.Sebagai kesimpulan, pemeriksaan rapid UBC memberikan nilai PPV yang cukup tinggi terkait temuan sistoskopi tumor buli dan hasil histopatologi karsinoma sel transisional buli. Pada penelitian awal ini, pemeriksaan Rapid UBC dapat menjadi pemeriksaan penunjang yang menjanjikan dan berguna untuk evaluasi cepat pada kasus dengan dugaan tumor buli. Dibutuhkan studi lanjutan dengan jumlah sampel yang lebih besar untuk mengevaluasi nilai diagnostik pemeriksaan Rapid UBC.Kata kunci: karsinoma buli, transisional sel; diagnosis; marker tumor; UBC
Penggunaan Uji Imunohistokimia BerEP4 sebagai Gold Standard Deteksi Karsinoma Sel Basal SUKMAWATI TANSIL TAN; ANTHONY PAULO SUNJAYA
Indonesian Journal of Cancer Vol 10, No 3 (2016): July - September 2016
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1725.547 KB) | DOI: 10.33371/ijoc.v10i3.435

Abstract

ABSTRACTBasal Cell Carcinoma (BCC) is the most common malignant type of skin cancer found in the world today with a 3-10% increase in incidence each year. In Indonesia, BCC is one of the major types of skin cancer found. Therefore a method needs to be developed that can detect BCC at the early stages to prevent late diagnosis of BCC which may lead to metastasis causing disabilities to patients and increasing treatment costs. Various studies have shown BerEP4 as an effective and efficient tool that can be used for early diagnosis and prevention of recurrence post-surgery. This study aims to evaluate the use of BerEP4 in detecting early BCC cells and its potential as a gold standard. The use of BerEP4 immunohistochemistry testing as a gold standard for the routine examination for cases of BCC is expected to be able to increase and improve early diagnosis as well as prevent recurrence postsurgery.ABSTRAKKarsinoma Sel Basal (KSB) merupakan jenis kanker kulit yang paling banyak ditemukan di dunia saat ini dan terjadi peningkatan 3-10% jumlah penderita KSB setiap tahun. Di Indonesia, KSB merupakan salah satu jenis kanker kulit yang utama. Oleh karena itu, dibutuhkan suatu metode yang dapat mendeteksi KSB pada stadium awal karena diagnosis yang terlambat dapat menyebabkan KSB bermetastasis sehingga menjadi sulit ditangani, meningkatkan risikopenderita menjadi cacat, dan memerlukan biaya pengobatan yang mahal. Berbagai penelitian telah menunjukkan bahwa BerEP4 merupakan cara yang efektif dan efisien untuk melakukandiagnosis dini dan pencegahan rekurensi pasca-operasi pengangkatan KSB. Penelitian ini bertujuan untuk menilai manfaat BerEP4 dalam mendeteksi sel KSB tahap dini. Diharapkan penggunaan uji imunohistokimia BerEP4 bisa menjadi gold standard pemeriksaan rutin pada kasus-kasus KSB sehingga mampu meningkatkan dan mempermudah diagnosis dini KSB serta mencegah terjadinya rekurensi pasca-operasi pengangkatan KSB.
Diabetes Mellitus as One of the Risk Factors Contribute to Carcinogenesis Noorwati Sutandyo
Indonesian Journal of Cancer Vol 14, No 2 (2020): June
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (526.981 KB) | DOI: 10.33371/ijoc.v14i2.703

Abstract

Diabetes mellitus (DM) and cancer are both global diseases whose numbers continue to grow. Higher risk of developing cancer in diabetic patients, especially in liver, endometrial, pancreatic, kidney, colorectal, bladder, and breast cancer, was already shown in several previous studies. This review will explain the possible DM pathogenesis that plays a role in carcinogenesis using the simple but thorough concept of insulin resistance, hyperglycemia, and chronic inflammation. By knowing the link, it is hoped that this review can be useful in developing cancer prevention plans for those with diabetes.
Brakhiterapi Pada Kanker Lidah di Rumah Sakit Kanker Dharmais Defrizal Defrizal
Indonesian Journal of Cancer Vol 1, No 2 (2007): Apr - Jun 2007
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (992.097 KB) | DOI: 10.33371/ijoc.v1i2.11

Abstract

Dilakukan interstitial brakhiterapi pada 19 pasien kanker lidah di departemen radioterapi RS.Kanker Dharmais. Pasien terdiri dari 14 orang laki-laki, 5 orang perempuan dengan rentang usia 20 hingga 75 tahun dan hasil histopatologik pasien tersebut adalah karsinoma sel skuamosa. Pasien terdiri dari 9 orang stadium II sebanyak, 7 orang stadium III, 1 orang stadium IV dan 2 orang dengan residif lokal. Seluruh pasien mendapat radiasi ekstema dengan dosis 46 - 60 Gy dan dilanjutkan dengan interstitial brakhiterapi dengan menggunakan iridium 192. Hasil yang didapatkan adalah 17 pasien dengan respon komplit, 2 pasien dengan respon parsial dan tidak didapatkan adanya komplikasi. Dari hasil tersebut dapat disimpulkan bahwa dengan terapi radiasi saja (kombinasi antara radiasi eksternal dan interstitial brakhiterapi) memberikan respon terapi yang baik.
Effect of Initial Cytoreductive Nephrectomy with Target Therapy versus Target Therapy Alone in Metastatic Renal Cell Carcinoma: A Single Institutional Study Rasha Mohamed Abdel Latif; Kamel Farag Selim
Indonesian Journal of Cancer Vol 13, No 2 (2019): June
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1039.816 KB) | DOI: 10.33371/ijoc.v13i2.635

Abstract

Background: The metastatic renal cell carcinoma (mRCC) patients treated with upfront cytoreductive nephrectomy (CN) combined with immunotherapy results in overall survival (OS) improvement. It is unclear whether mRCC patients treated with target therapy will also benefit from CN. The aim of the study was to identify the benefit of upfront CN followed by targeted therapy (TTs) versus TTs alone on OS of patients with mRCC, and to evaluate pre-operative variables for selection of patients who would benefit from CN, and also the response rate (RR) and the progression-free survival (PFS). Methods: A retrospective study was performed in our Department on patients diagnosed with mRCC within the period of January 2013 to April 2018. Data that were collected included patients and tumor characteristics. Patients were divided into two groups: 1) received upfront CN followed by TTs, and the 2) one treated with TTs alone. Survival analysis was performed using Kaplan-Meier method, univariate analysis with log-rank test was used to estimate predictors of survival in the CN group, and Cox regression was used for multivariate analysis. Results: The median OS of all patients was 14 months, and was 19 and 10.5 months in CN and non-CN respectively with significant difference (P˂0.001). Lower hemoglobin level (P=0.012), high neutrophil count (P˂0.001), low albumin level (P=0.006), number of metastatic sites ≥3 (P˂0.001), and patients with number of risk factors ≥3 (P˂0.001) have a negative impact on OS in CN group. Conclusions: Upfront CN before TTs in mRCC carries better survival than TTs alone. Five pre-operative variables (i.e. hemoglobin level, neutrophil count, albumin level, number of metastatic sites, and number of risk factors) were identified as suitable for selection of patients who will benefit from CN.
The Accuracy of Confocal Laser Endomicroscopy in Diagnosing Bladder Cancer: A Systematic Review & Meta-Analyses Hafizar Hafizar; Etriyel MYH
Indonesian Journal of Cancer Vol 15, No 4 (2021): December
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1183.825 KB) | DOI: 10.33371/ijoc.v15i4.804

Abstract

Background: Multiple advancements of endoscopic technology were designed to enhance the sensitivity and specificity of the diagnostic tools of bladder cancer; thus, we perform a meta-analysis to compare diagnostic performance between confocal laser endomicroscopy (CLE) and biopsy for detecting bladder cancer.Methods: We compared CLE’s accuracy in diagnosing bladder cancer reported by studies obtained from the electronic database MEDLINE, CENTRAL, and CINAHL, from May to June 2020. The pooled effect estimate was calculated employing the DerSimonian and Laird random-effects model. We only included moderate to high-quality studies, which had been assessed by the QUADAS-2 tool.Results: Eight studies were included in this review; five of those were good-quality studies. A total of 519 samples from 345 patients were included in the pooled effect estimate calculation. Pooled sensitivity and specificity of CLE in diagnosing bladder cancer were 90.2% (0.86, 0.93) and 78.1% (0.71, 0.85), respectively. The use of white-light cystoscopy (WLC) before CLE increased its specificity (56.8% versus 84.6%). Pooled sensitivity and specificity of CLE in predicting lowgrade lesion were 73% (0.66, 0.80) dan 83% (0.78, 0.87), respectively. Meanwhile, pooled sensitivity and specificity of CLE in predicting high-grade lesion were 73% (0.66, 0.78) and 79% (0.73, 0.83), respectively.Conclusions: CLE has good accuracy in distinguishing malignant and benign tumors. Grading tumors with this modality is also accurate. The use of probe CLE (pCLE), coupled with WLC, will increase its specificity.
Faktor Risiko Kanker Payudara pada Pasien Wanita di Rumah Sakit Kanker Dharmais, Jakarta Devi Nur Oktaviana; Evy Damayanthi; Kardinah -
Indonesian Journal of Cancer Vol 6, No 3 (2012): Jul - Sep 2012
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v6i3.203

Abstract

Penelitian ini bertujuan untuk mengetahui faktor risiko kanker payudara pada pasien kanker payudara wanita di Rumah Sakit Kanker Dharmais (RSKD). Penelitian ini bersifat observasional analitik dengan desain Hospital Based Case Control Study. Contoh dalam penelitian ini terbagi dalam dua kelompok, 24 orang kelompok kasus dan 24 orang kelompok kontrol. Analisis bivariat dilakukan dengan analisis Chi-Square dan analisis tabel 2 x 2. Analisis multivariat dilakukan dengan analisis regresi logistik berganda. Tidak terdapat hubungan antara usia, status gizi, pengetahuan gizi, konsumsi makanan berlemak, konsumsi sayur, konsumsi buah, riwayat kanker payudara pada keluarga, usia menstruasi pertama, lama menyusui, lama menggunakan alat kontrasepsi hormonal, lama melakukan aktivitas fisik, dan perokok pasif terhadap kejadian kanker payudara. Berdasarkan analisis bivariat, tinggi konsumsi makanan diawetkan dan dibakar berisiko 9,308 kali terkena kanker payudara (OR=9,308 dengan 95% CI: 1,778-48,723) dibandingkan dengan rendah konsumsi makanan diawetkan dan dibakar. Berdasarkan analisis multivariat, tidak ada variabel yang berpengaruh terhadap kejadian kanker payudara.Kata kunci: kanker payudara, faktor risiko
Ekspresi CD44 dan ALDH1 (Penanda Sel Punca Kanker) sebagai Prediktor Respons Kemoterapi Neoadjuvant Cisplatin pada Kanker Serviks Uteri Stadium IIB GUNAWAN RUSULDI; BRAHMANA ASKANDAR
Indonesian Journal of Cancer Vol 11, No 3 (2017): July - September 2017
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1610.351 KB) | DOI: 10.33371/ijoc.v11i3.511

Abstract

Giving neoadjuvant chemotherapy allows stage IIB cervical cancer having surgery with a chance of avoiding radiotherapy. Giving neoadjuvant chemotherapy in several studies produces varied responsses. The method for predicting whether a cervical cancer patient experiences responsse of treatment in neoadjuvant chemotherapy becomes important thing, considering the side effects of chemotherapy, time, and cost. Sub-population of cells called Cancer Stem Cells (CSC) is something which is alleged to be responssible for cancer growth, recurrence and the process of resistance to chemotherapy and radiation. Some researchers proved that this occurrence is due to the cancer stem cell which is surviving after chemotherapy. The presence of cervical cancer stem cells is shown by CD44 and ALDH1. This research proves there is connection between the expression of CD44 and ALDH1 as a marker of cancer stem cells with cisplatin neoadjuvant chemotherapy responsse and correlation in the increasing of expression of CD44 and ALDH1 (a marker of cancer stem cells) against cisplatin neoadjuvant chemotherapy resistance in cervical cancer stage IIB. Design observational analytic form prospectively study with total samples 30 patient cervical cancer IIB from December 2016 until May 2017. Clinical and MRI examination and cervical biopsy to immunohistochemistry examination for CD44 and ALDH1. Administration of neoadjuvant chemotherapy (NAC) cisplatin 50 mg/m2 4 times everyweek. After 2–3 weeks after last NAC, repeat to MRI examination. Assesment responsse therapy with RECIST criteria. Chemotherapy responsse obtained Partial Responsse (PR) 12 pts (40%), Stable Dissease (SD) 12 pts (40%), and Progressive Dissease (PD) 6 pts (20%). There is Relationship Strong Negative Correlation Expression CD44 with chemotherapy responsse (Spearman test rs= - 0.903 and p= 0.000); analysis ROC curve obtained cut off 37.00 and 76.00 with accuration 86,67%. Also there is Relationship Strong Negative Correlation Expression ALDH1 with chemotherapy responsse (Spearman test rs= - 0.893 and p= 0.000); analysis ROC curve obtained cut off 55.00 and 94.00 with accuration 93.33%. Analysis with Spearman there is Strong Correlation between CD44 with ALDH1 (rs= 0.907 and p=0.000). And ALDH1 is more better predictor than CD44 to predict chemoterapy responsse (beta coeficient CD44 = -0.389, ALDH1= -0.551). CD44 and ALDH1 expression can be used a predictor of responsse to neoadjuvant chemotherapy cisplatin in patient with cervical cancer IIB; and ALDH1 more better as predictor than CD44. ABSTRAK Pemberian kemoterapi neoadjuvant memungkinkan kanker serviks stadium IIB dapat dilakukan pembedahan dengan kemungkinan menghindari pemberian radioterapi. Pemberian kemoterapi neoadjuvant pada beberapa penelitian memberikan hasil yang bervariatif. Metode untuk memprediksi apakah seseorang penderita kanker serviks mengalami respons terapi pada kemoterapi neoadjuvant menjadi hal yang penting, mengingat efek samping kemoterapi, waktu, dan biaya. Subpopulasi sel yang dinamakan sel punca kanker/cancer stem cells (CSC) tersebutlah yang diduga bertanggung jawab terhadap terjadinya pertumbuhan kanker, kekambuhan, serta proses resistansi terhadap kemoterapi dan radiasi. Beberapa peneliti membuktikan bahwa kejadian seperti ini disebabkan sel punca kanker yang tetap bertahan hidup pasca-kemoterapi. Keberadaan sel punca kanker serviks ditunjukkan oleh CD44 dan ALDH1. Penelitian ini membuktikan adanya hubungan antara ekspresi CD44 dan ALDH1 sebagai penanda sel punca kanker dengan respons kemoterapi neoadjuvant cisplatin; dan terdapat korelasi peningkatan ekspresi CD44 dan ALDH1 (penanda sel punca kanker) terhadap resistansi kemoterapi neoadjuvant cisplatin pada kanker serviks stadium IIB. Penelitian ini menggunakan rancangan analitik observasional secara prospektif dengan jumlah sampel 30 pasien kanker serviks IIB mulai Desember 2016 sampai Mei 2017. Pemeriksaan klinis dan MRI serta biopsi serviks dilakukan, kemudian dilanjutkan pemeriksaan imunohistokimia CD44 dan ALDH1. Pemberian kemoterapi neoadjuvant (NAC) cisplatin 50 mg/m2 dilakukan 4 kali setiap minggu. Setelah 2–3 minggu NAC terakhir pasien dilakukan pemeriksaan ulang klinis ataupun MRI untuk menilai respons terapi secara kriteria RECIST. Respons kemoterapi menunjukkan partial response (PR) 12 subjek (40%), stable dissease (SD) 12 subjek (40%), and progressive dissease (PD) 6 subjek (20%). Terdapat korelasi negatif kuat antara ekspresi CD44 dengan respons terapi (Spearman test rs= - 0,903 dan p= 0,000). Analisis kurva ROC mendapatkan nilai cut off 37,00 dan 76,00 dengan nilai akurasi sebesar 86,67 %. Juga terdapat korelasi negatif kuat antara ekspresi ALDH1 dengan respons terapi (Spearman test rs= - 0,893 and p= 0,000); dilanjutkan analisis kurva ROC didapatkan nilai cut off 55,00 dan 94,00 dengan nilai akurasi sebesar 93,33%. Analisis dengan Spearman didapatkan hubungan korelasi kuat antara ekspresi CD44 dengan ALDH1 (rs= 0,907 dan p=0,000). ALDH1 merupakan prediktor yang lebih baik daripada CD44 (beta coeficient CD44 = -0,389; ALDH1= -0,551). Ekspresi CD44 dan ALDH1 (penanda sel punca kanker) dapat dipakai sebagai prediktor respons kemoterapi neoadjuvant cisplatin pada kanker serviks IIB. ALDH1 merupakan prediktor yang lebih baik daripada CD44

Page 29 of 57 | Total Record : 562

 27   28   29   30   31 

Filter by Year

2007 2025


Reset
Filter By Issues
All Issue Vol 19, No 3 (2025): September Vol 19, No 2 (2025): June Vol 19, No 1 (2025): March Vol 18, No 4 (2024): December Vol 18, No 3 (2024): September Vol 18, No 2 (2024): June Vol 18, No 1 (2024): March Vol 17, No 4 (2023): December Vol 17, No 3 (2023): September Vol 17, No 2 (2023): June Vol 17, No 1 (2023): March Vol 16, No 4 (2022): December Vol 16, No 3 (2022): September Vol 16, No 2 (2022): June Vol 16, No 1 (2022): March Vol 15, No 4 (2021): December Vol 15, No 3 (2021): September Vol 15, No 2 (2021): June Vol 15, No 1 (2021): March Vol 14, No 4 (2020): December Vol 14, No 3 (2020): September Vol 14, No 2 (2020): June Vol 14, No 1 (2020): March Vol 13, No 4 (2019): December Vol 13, No 3 (2019): September Vol 13, No 2 (2019): June Vol 13, No 1 (2019): March Vol 12, No 4 (2018): October-December Vol 12, No 3 (2018): July-September Vol 12, No 2 (2018): April-June Vol 12, No 1 (2018): Jan - Mar Vol 11, No 4 (2017): October- December 2017 Vol 11, No 3 (2017): July - September 2017 Vol 11, No 2 (2017): April - June Vol 11, No 1 (2017): Jan-Mar Vol 10, No 4 (2016): October - December 2016 Vol 10, No 3 (2016): July - September 2016 Vol 10, No 2 (2016): April - June 2016 Vol 10, No 1 (2016): Jan - Mar 2016 Vol 9, No 4 (2015): Okt - Des 2015 Vol 9, No 3 (2015): Jul - Sept 2015 Vol 9, No 2 (2015): April-Juni 2015 Vol 9, No 1 (2015): Jan - Mar 2015 Vol 8, No 4 (2014): Oct - Dec 2014 Vol 8, No 3 (2014): Jul - Sep 2014 Vol 8, No 2 (2014): April-Juni 2014 Vol 8, No 1 (2014): Jan - Mar 2014 Vol 7, No 4 (2013): Oct - Dec 2013 Vol 7, No 3 (2013): Jul - Sep 2013 Vol 7, No 2 (2013): Apr - Jun 2013 Vol 7, No 1 (2013): Jan - Mar 2013 Vol 6, No 4 (2012): Oct - Dec 2012 Vol 6, No 3 (2012): Jul - Sep 2012 Vol 6, No 2 (2012): Apr - Jun 2012 Vol 6, No 1 (2012): Jan - Mar 2012 Vol 5, No 4 (2011): Oct - Dec 2011 Vol 5, No 3 (2011): Jul - Sep 2011 Vol 5, No 2 (2011): Apr - Jun 2011 Vol 5, No 1 (2011): Jan - Mar 2011 Vol 4, No 4 (2010): Oct - Dec 2010 Vol 4, No 3 (2010): Jul - Sep 2010 Vol 4, No 2 (2010): Apr - Jun 2010 Vol 4, No 1 (2010): Jan - Mar 2010 Vol 3, No 4 (2009): Oct - Dec 2009 Vol 3, No 3 (2009): Jul - Sep 2009 Vol 3, No 2 (2009): Apr - Jun 2009 Vol 3, No 1 (2009): Jan - Mar 2009 Vol 2, No 4 (2008): Oct - Dec 2008 Vol 2, No 3 (2008): Jul - Sep 2008 Vol 2, No 2 (2008): Apr - Jun 2008 Vol 2, No 1 (2008): Jan - Mar 2008 Vol 1, No 4 (2007): Oct - Dec 2007 Vol 1, No 3 (2007): Jul - Sep 2007 Vol 1, No 2 (2007): Apr - Jun 2007 Vol 1, No 1 (2007): Jan - Mar 2007 More Issue